{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:08:04Z","timestamp":1792868884025,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.yebeh.2021.107815","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:08:30Z","timestamp":1614298110000},"page":"107815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7046-8280","authenticated-orcid":false,"given":"Gianni","family":"Cutillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Tolba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-832X","authenticated-orcid":false,"given":"Lawrence J.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107815_b0005","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0015","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1212\/WNL.0000000000008741","article-title":"Clinical risk factors in SUDEP: a nationwide population-based case-control study","volume":"94","author":"Sveinsson","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1528-1167.2005.00411.x","article-title":"Sudden unexpected death in epilepsy: a review of incidence and risk factors","volume":"46","author":"Tomson","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0025","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1474-4422(13)70214-X","article-title":"Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study","volume":"12","author":"Ryvlin","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107815_b0030","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(11)70193-4","article-title":"Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials","volume":"10","author":"Ryvlin","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107815_b0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1167.2011.03360.x","article-title":"Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk","volume":"53","author":"Lamberts","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","article-title":"Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Acade","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","article-title":"Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic\u2013clonic seizures","volume":"313","author":"Mattson","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107815_b0050","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic\u2013clonic seizures in adults","volume":"327","author":"Mattson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107815_b0055","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/epi.12765","article-title":"Prevention of generalized tonic-clonic seizures in refractory focal epilepsy: a meta-analysis","volume":"55","author":"Hemery","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double\u2010blind, randomized, placebo\u2010controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0070","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ane.12103","article-title":"Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures","volume":"127","author":"Ko","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107815_b0090","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","article-title":"Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study","volume":"46","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0095","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.WNL.0000068024.20285.65","article-title":"Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures","volume":"60","author":"French","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2008.01954.x","article-title":"Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial","volume":"50","author":"Lee","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0105","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/WNL.57.10.1774","article-title":"Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures","volume":"57","author":"Faught","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0110","article-title":"Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)","volume":"2020","author":"Maguire","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.107815_b0115","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107815_b0125","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0130","doi-asserted-by":"crossref","unstructured":"Elger C, Hal\u00e1sz P, Maia J, Almeida L, Soares-da-Silva P, BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454\u201363. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01946.x.","DOI":"10.1111\/j.1528-1167.2008.01946.x"},{"key":"10.1016\/j.yebeh.2021.107815_b0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0140","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1528-1157.1991.tb04668.x","article-title":"Felbamate: a clinical trial for complex partial seizures","volume":"32","author":"Theodore","year":"1991","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0145","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1528-1157.1995.tb00468.x","article-title":"Felbamate monotherapy: implications for antiepileptic drug development","volume":"36","author":"Theodore","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0150","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1528-1157.1994.tb02513.x","article-title":"Gabapentin (neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study","volume":"35","author":"Anhut","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0155","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0160","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1212\/01.wnl.0000277698.33743.8b","article-title":"Lamotrigine extended-release as adjunctive therapy for partial seizures","volume":"69","author":"Naritoku","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1528-1157.1993.tb02417.x","article-title":"Outcomes of add-on treatment with lamotrigine in partial epilepsy","volume":"34","author":"Smith","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1996.tb07060.x","article-title":"Controlled trial of lamotrigine (Lamictal\u00ae) for treatment-resistant partial seizures","volume":"94","author":"Boas","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107815_b0175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0180","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0185","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0190","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107815_b0195","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1528-1167.2009.02160.x","article-title":"Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0200","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1528-1167.2010.02729.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures","volume":"52","author":"Biton","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":"Tiagabine for complex partial seizures: a randomized, add-on, dose- response trial","volume":"55","author":"Uthman","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2021.107815_b0210","first-page":"182","article-title":"Tiagabine: phase II study of efficacy and safety in adjunctive treatment of partial seizures","volume":"34","author":"Crawford","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0920-1211(95)00006-V","article-title":"Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial","volume":"21","author":"Richens","year":"1995","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107815_b0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-1211(97)00082-X","article-title":"A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures","volume":"30","author":"K\u00e4lvi\u00e4inen","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107815_b0225","first-page":"1162","article-title":"A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy","volume":"41","author":"Sharief","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0230","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0235","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1528-1157.1999.tb01596.x","article-title":"Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial","volume":"40","author":"Korean Topiramate Study Group","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107815_b0240","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0245","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107815_b0250","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Low-dose topiramate in adults with treatment-resistant partial-onset seizures","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurol Scand"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021000494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021000494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:39:54Z","timestamp":1761503994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":50,"alternative-id":["S1525505021000494"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107815","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107815"}}